Compare ADMA Biologics Inc (ADMA) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs QUALCOMM, Inc. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while QUALCOMM, Inc. trades at $186.44 (market cap $192.85B). The key difference: QUALCOMM, Inc. is far larger — about 90.5× ADMA Biologics Inc's market cap, and QUALCOMM, Inc. pays a 2.01% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | QCOM | |
|---|---|---|
Market Cap | $2.13B | $192.85B |
Sector | Health | Technology |
52-Week High | $20.38 | $251.10 |
52-Week Low | $7.60 | $124.07 |
Enterprise Value | $2.20B | $198.32B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Qualcomm (QCOM) trades at $186.48, up 5.8% in the last 24 hours, reflecting strong momentum. The stock exhibits a bearish technical signal but has consistently beaten earnings expectations in recent quarters. Revenue for 2025 reached $44.28 billion, with a net income margin of 22.31%, though this represents a decline from the previous year. The company is actively diversifying into AI, automotive, and data centers, as highlighted at recent industry events like COMPUTEX 2026.
The outlook is mixed; analyst consensus is a 'Buy' with a $221.21 price target, indicating potential upside, but near-term risks include margin pressures and intense competition in the PC and smartphone chip markets. The stock's valuation, with a P/E of 20.05, appears reasonable relative to growth prospects, but investors must weigh the diversification strategy against persistent market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
